Tesamorelin (Egrifta)
Stabilized GHRH analog, FDA-approved for HIV-associated lipodystrophy
At a glance
What it is: Stabilized GHRH analog, FDA-approved for HIV-associated lipodystrophy.
Primary research applications:
- HIV-associated visceral adipose tissue (VAT) excess — FDA-approved
- Investigational: non-alcoholic fatty liver disease
Editorial summary: Tesamorelin is a rare FDA-approved GHRH analog, with demonstrated efficacy at reducing visceral fat in people with HIV-associated lipodystrophy. Off-label use for body recomposition in otherwise-healthy adults lacks comparable RCT data.
What is Tesamorelin?
Tesamorelin is a synthetic GHRH analog with a fatty-acid modification that stabilizes it against enzymatic degradation. It was approved by the FDA in 2010 as Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.[1]
Mechanism of action
Like other GHRH analogs, tesamorelin binds the pituitary GHRH receptor to stimulate pulsatile endogenous GH release, elevating IGF-1. Its modified structure allows once-daily subcutaneous dosing.
What the research shows
The peer-reviewed literature on Tesamorelin is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Reduces visceral fat in HIV lipodystrophy | Phase 3 RCTs | Supported |
| Reduces liver fat | Growing human evidence | Supported |
| Produces general body recomposition in healthy adults | Limited controlled data outside HIV population | Preliminary |
| Carries the same IGF-1 elevation concerns as other GHRH analogs | Mechanism | Supported |
Reported user experiences
How the research describes administration
FDA label: 2 mg subcutaneous injection daily. Refer to the product labeling and prescribing physician.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Tesamorelin is an actual FDA-approved peptide drug with solid Phase 3 data in its indication. Its use for general body recomposition rests on extrapolation and smaller studies. Of the GH-related peptides, it has the most substantive regulatory dossier.
Frequently asked questions
Is tesamorelin FDA-approved?
Yes, as Egrifta, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Does tesamorelin work for NAFLD?
Growing evidence, including in HIV-positive patients, suggests reductions in liver fat. NAFLD-specific trials are ongoing in non-HIV populations.
Can I use tesamorelin for general fat loss?
Off-label use exists but trial evidence in non-HIV populations is limited. Cost and insurance coverage are also significant considerations.
References
- FDA approval package for Egrifta (tesamorelin) — BLA 022505. 2010. See also Stanley TL, Grinspoon SK. Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices. Growth Horm IGF Res. 2015;25(2):59-65. https://pubmed.ncbi.nlm.nih.gov/25555516/
- Falutz J, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation. N Engl J Med. 2007;357:2359-70. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA. 2014;312(4):380-9. https://pubmed.ncbi.nlm.nih.gov/25038357/